By Dean Seal
Alcon has agreed to acquire the medical-technology company Lensar in a deal that could be worth up to $430 million.
The eye-care company said Monday that it would pay $14 for each Lensar share in cash, and an additional $2.75 per share based on certain milestones for Lensar's products in 2026 and 2027.
The transaction includes Lensar's ALLY Robotic Cataract Laser Treatment System, its proprietary Streamline software and its legacy laser system, which should benefit Alcon's laser-assisted cataract surgery offering.
The deal is expected to close in mid-to-late 2025, subject to approval from regulators and Lensar's shareholders.
Shares of Lensar were halted at $14.57 in premarket trading.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
March 24, 2025 08:21 ET (12:21 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.